BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Trevena, Inc. to Present First-in-Man Study Results for Mu-Opioid Biased Ligand TRV130


3/18/2013 9:59:47 AM

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Trevena, Inc., the leader in the discovery and development of G-protein coupled receptor (GPCR) biased ligands, announced today that Michael Lark, Ph.D., Chief Scientific Officer, will present the results of a Phase 1 first-in-man study on the safety, tolerability, and pharmacology of TRV130 in healthy volunteers, as a poster at the American Academy of Neurology meeting, to be held in San Diego on March 16th through 23rd, 2013. The poster will be presented on Tuesday, March 19th. In this study, which was completed in 2012, TRV130 was safe and generally well-tolerated, and showed pharmacodynamic effects that were consistent with its exciting preclinical profile. TRV130’s pharmacokinetic profile was also shown to be suitable for an intermittent-use intravenous drug. Trevena is developing TRV130 for the intravenous treatment of acute moderate-to-severe post-operative pain. The data supports TRV130 progression to its next clinical study, in which analgesic efficacy and tolerability will be compared directly with intravenous morphine, a gold-standard post-operative analgesic.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->